“I’m currently sitting 100 feet away from a giant lab full of robots where we can do up to 2.2 million experiments a week,” says Dr. Chris Gibson, the Co-Founder and CEO of Recursion, a company whose mission is to create a more efficient path to drug discovery. You are going to hear a lot of mind-boggling numbers from Chris in today’s Raise the Line episode, but they all boil down to this: advances in genetics, computing, artificial intelligence, mRNA capability and other technologies are all converging to accelerate the testing of drugs at an incredible pace. This is particularly good news for people with rare diseases who are often in a race against time for development of therapies. Although only founded nine years ago, Recursion already has four programs in clinical trials. A key factor in this success is a bold departure from the traditional hypothesis-based approach to science driven by lab failures Chris experienced while earning his MD-PhD. Once he and his colleagues cast aside their bias about what was driving the disease in question, they achieved success in animal testing. “We just modeled the genetic loss of function because we knew that incontrovertibly to be true, and then asked the cells what was actually driving the disease and what could make it better.” Don’t miss this fascinating look at reengineering drug discovery through gene mapping, training neural networks and other leading-edge technology.
Mentioned in this episode: https://www.recursion.com/
If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast
